01:08 , Feb 1, 2019 |  BC Week In Review  |  Company News

AZ, UPMC in value-based agreement for Brilinta

To reduce out-of-pocket costs for Medicare patients, AstraZeneca plc (LSE:AZN; NYSE:AZN) signed a value-based contract with UPMC Health Plan for Brilinta ticagrelor that links reimbursement of the drug to cardiovascular outcomes following a recent hospitalization...
22:22 , Jan 28, 2019 |  BC Extra  |  Company News

AZ, UPMC in value-based agreement for Brilinta

To reduce out-of-pocket costs for Medicare patients, AstraZeneca plc (LSE:AZN; NYSE:AZN) signed a value-based contract with UPMC Health Plan for Brilinta ticagrelor that links reimbursement of the drug to cardiovascular outcomes following a recent hospitalization...
19:20 , Dec 21, 2018 |  BC Week In Review  |  Clinical News

Idorsia's P2RY12 antagonist inhibits platelet aggregation within 15 minutes

Idorsia Ltd. (SIX:IDIA) said single subcutaneous injections of selatogrel (ACT-246475) inhibited platelet aggregation within 15 minutes with its maximum effect extending over 4-8 hours depending on the dose in a pair of Phase II trials...
01:31 , Sep 2, 2017 |  BioCentury  |  Strategy

Breach of contract

Merck & Co. Inc. Chairman and CEO Kenneth Frazier’s resignation in August from a White House advisory council was an act of principle, and a reminder that 30 years ago Merck was one of the...
23:08 , Jun 19, 2017 |  BC Extra  |  Politics & Policy

SCOTUS sides with BMS in jurisdictional case

In an 8-1 decision Monday, the U.S. Supreme Court ruled that out-of-state residents could not enter a case brought against Bristol-Myers Squibb Co. (NYSE:BMY) in California, reversing an earlier state court's decision that BMS's "extensive...
17:15 , Jun 2, 2017 |  BC Week In Review  |  Company News

AZ and Harvard Pilgrim sign two outcomes-based drug pricing contracts

Regional insurer Harvard Pilgrim Health Care Inc. (Boston, Mass.) signed two outcomes-based drug pricing contracts with AstraZeneca plc (LSE:AZN; NYSE:AZN). The insurer signed a three-year contract for AZ’s Brilinta ticagrelor, which is marketed in the...
18:31 , Mar 31, 2017 |  BC Week In Review  |  Clinical News

Xarelto: Ph II GEMINI-ACS-1 data

The double-blind, international Phase II GEMINI-ACS-1 trial in 3,037 patients with ACS showed that twice-daily 2.5 mg oral Xarelto plus clopidogrel or Brilinta ticagrelor led to no significant difference in the rate of TIMI clinically...
19:55 , Mar 14, 2017 |  BC Week In Review  |  Clinical News

Savaysa: Ph IIIb ENTRUST-AF PCI started

Daiichi began the open-label, international Phase IIIb ENTRUST-AF PCI trial to evaluate 30 and 60 mg oral Savaysa once daily vs. a vitamin K antagonist for 12 months in 1,500 patients. Patients will also receive...
16:16 , Nov 30, 2016 |  BC Week In Review  |  Clinical News

Pradaxa: Completed Ph III enrollment

Boehringer completed enrollment of 2,727 patients in the open-label, international Phase III RE-DUAL PCI trial comparing 110 and 150 mg oral Pradaxa twice daily plus clopidogrel or Brilinta ticagrelor vs. triple antithrombotic therapy comprising warfarin,...
21:21 , Nov 18, 2016 |  BC Week In Review  |  Clinical News

Xarelto: Ph IIIb PIONEER AF-PCI data

The open-label, international Phase IIIb PIONEER AF-PCI trial in 2,124 patients with non-valvular AF who received background antiplatelet therapy following PCI with stenting showed that once-daily15 mg oral Xarelto plus single antiplatelet therapy (clopidogrel or...